Purine Metabolites in Tumor-Derived Exosomes May Facilitate Immune Escape of Head and Neck Squamous Cell Carcinoma.
HNSCC
TEX
adenosine
exosomes
extracellular vesicles
head and neck cancer
purine metabolites
purinergic signaling
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jun 2020
17 Jun 2020
Historique:
received:
26
05
2020
revised:
10
06
2020
accepted:
15
06
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
21
6
2020
Statut:
epublish
Résumé
Body fluids of patients with head and neck squamous cell carcinoma (HNSCC) are enriched in exosomes that reflect properties of the tumor. The aim of this study was to determine whether purine metabolites are carried by exosomes and evaluate their role as potential contributors to tumor immune escape. The gene expression levels of the purine synthesis pathway were studied using the Cancer Genome Atlas (TCGA) Head and Neck Cancer database. Exosomes were isolated from supernatants of UMSCC47 cells and from the plasma of HNSCC patients (
Identifiants
pubmed: 32560461
pii: cancers12061602
doi: 10.3390/cancers12061602
pmc: PMC7352909
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften
ID : LPDS 2017-12 and LPDS 2019-02
Organisme : NIDDK NIH HHS
ID : P30 DK079307
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL069846
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK091190
Pays : United States
Organisme : NIH HHS
ID : HL109002, DK091190, HL069846, DK068575, DK079307, R01-CA 168628
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109002
Pays : United States
Références
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1251-1267
pubmed: 32313990
Front Oncol. 2018 Oct 12;8:445
pubmed: 30370252
Theranostics. 2017 Aug 23;7(16):3824-3841
pubmed: 29109780
Int J Cancer. 2013 Nov;133(9):2013-23
pubmed: 23417723
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
Carcinogenesis. 2020 Jul 10;41(5):625-633
pubmed: 31245809
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
Oncoimmunology. 2019 Apr 15;8(7):1593808
pubmed: 31143515
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Int J Mol Sci. 2019 Jul 14;20(14):
pubmed: 31337156
J Biol Chem. 2009 Nov 27;284(48):33097-106
pubmed: 19801686
Am J Physiol Lung Cell Mol Physiol. 2019 Apr 1;316(4):L691-L700
pubmed: 30758991
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Front Immunol. 2014 Apr 10;5:160
pubmed: 24782865
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
Mol Neurobiol. 2017 Jul;54(5):3271-3285
pubmed: 27130268
Am J Physiol Regul Integr Comp Physiol. 2019 Jun 1;316(6):R783-R790
pubmed: 30789788
Clin Exp Immunol. 2014 Aug;177(2):531-43
pubmed: 24749746
Cancer Lett. 2017 Oct 28;407:84-92
pubmed: 28807820
Physiol Rep. 2014 May 28;2(5):
pubmed: 24872359
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Haematologica. 2011 Sep;96(9):1302-9
pubmed: 21606166
Front Pharmacol. 2013 Mar 06;4:21
pubmed: 23508692
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739402
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
Curr Protoc Immunol. 2019 Dec;127(1):e91
pubmed: 31763776
J Biol Chem. 2010 Sep 3;285(36):27571-80
pubmed: 20558731
Angiogenesis. 2020 May 18;:
pubmed: 32419057
Cancer Res. 1989 Sep 15;49(18):5167-75
pubmed: 2766286
Exp Cell Res. 2019 May 15;378(2):149-157
pubmed: 30857972
Expert Opin Ther Targets. 2018 May;22(5):409-417
pubmed: 29634426
Purinergic Signal. 2020 May 22;:
pubmed: 32440820